Advocacy intelligence hub — real-time data for patient organizations
Bayer — PHASE3
Urmila DIwekar — PHASE1, PHASE2
Instituto Valenciano de Infertilidad, IVI VALENCIA — NA
Fang Wang — NA
ITB-Med LLC — PHASE2
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Tavneos
(avacopan)Orphan drugstandardChemoCentryx, Inc.
Complement 5a Receptor Antagonist [EPC]
12.1 Mechanism of Action Avacopan is a complement 5a receptor (C5aR) antagonist that inhibits the interaction between C5aR and the anaphylatoxin C5a. ...
Peter A Merkel, MD, MPH
University of Pennsylvania
📍 Tampa, Florida
Peter A. Merkel, MD, MPH, MD, MPH
University of Pennsylvania
📍 RADNOR, PA
David Jayne, MD, MD
Cambridge University Hospitals NHS Foundation Trust
📍 EDMOND, OK
John H Stone, MD
Massachusetts General Hospital and Harvard Medical School
Michael Walsh, MD
McMaster University
Christian Pagnoux, MD
MOUNT SINAI HOSPITAL